New therapies, such as IL-17 inhibitors (Secukinumab, ixekizumab) and IL-23 inhibitors (Risankizumab, guselkumab), are emerging as potential treatments for PRP [4]. The gene discussed is IL17A; the disease is familial pityriasis rubra pilaris.